NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tisento Therapeutics

Tisento Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://www.tisentotx.com/

Last Round

Series A

Jul 28, 2023

Est. Valuation

$100M

Total Funding Raised

$81M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Tisento Therapeutics is a biotechnology company developing novel medicines for the treatment of rare mitochondrial diseases, including Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

rare genetic diseasesmitochondrial diseasesMELASorphan diseasessGC stimulatorclinical-stage biotechzagociguatdrug developmentsoluble guanylate cyclase stimulatorbrain-penetrantdisease-modifying treatmentsMitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like EpisodesCNS diseasesoral medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tisento Therapeutics Comparables

Compare Tisento Therapeutics with similar companies based on industry and business-model similarity.

Tisento Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Pharming Group N.V.
85%
Khondrion
84%
Cyclerion Therapeutics
80%

Tisento Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 28, 2023

Key People

Founding team and executive leadership

Peter Hecht

Chief Executive Officer

Executive Team

G. Todd Milne

Chief Operating Officer

Executive Team

Tisento Therapeutics Investors

Notable investors and investment history

Tisento Therapeutics investors
InvestorRounds
Invus OpportunitiesSeries A
Sanofi VenturesSeries A
J. Wood Capital AdvisorsSeries A
VenrockSeries A
Polaris PartnersSeries A
InvusSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Monthly visitors increased 68% MoM.

  • May 22, 2025

    Presenting at the Reagan-Udall Foundation workshop on May 22, 2025.

Tisento Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tisento Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tisento Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range16
Year Founded2023
Last FundingJul 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.